Latest news with #RoyalDevonUniversityHealthcareNHSFoundationTrust
Business Wire
16-07-2025
- Business
- Business Wire
Royal Devon NHS selects Wolters Kluwer's UpToDate Enterprise Edition CDS solution
WALTHAM, Mass.--(BUSINESS WIRE)-- Wolters Kluwer Health announced today that the Royal Devon University Healthcare NHS Foundation Trust, an organization providing acute, community and specialist services across North Devon, Mid Devon, East Devon and Exeter, is the first NHS Trust to adopt UpToDate ® Enterprise Edition, a market-leading clinical decision support (CDS) solution. The Trust includes two acute hospitals and 17 community hospitals with over 1,100 beds. 'Deploying UpToDate Enterprise Edition is an important initiative in supporting our digital innovation strategy,' said Professor Adrian Harris, Chief Medical Officer at the Royal Devon University Healthcare NHS Foundation Trust. 'By leveraging the data, analytics and AI capabilities now available within UpToDate, we can further support medical education and optimize clinical decision-making, helping us to deliver the best possible care for all patients, and enabling our local population to stay well.' UpToDate Enterprise Edition offers harmonized content and solutions for the entire care team, empowering them to make more informed, confident, and impactful decisions. Using its AI-Enhanced Search capabilities, clinicians can now experience the efficiency of receiving highly focused verbatim answers from a market leading clinical decision solution using natural language queries—a time-saver for busy healthcare professionals. The AI-powered Analytics Dashboard offers healthcare organizations the ability to harness valuable organizational data for improved efficiency and educational opportunities. 'We are pleased to be working with The Royal Devon University Healthcare NHS Foundation Trust on the roll out of UpToDate Enterprise Edition,' said Christian Cella, Vice President, International Segment for Clinical Effectiveness at Wolters Kluwer Health. 'This is an innovative solution designed for forward thinking healthcare systems that are focused on transforming care delivery through integrated workflows that provide unparalleled content and faster time to answers.' Delivering high quality, efficient healthcare services 'Providing access to an evidence-based CDS like UpToDate helps reduce variability in care, drive better patient outcomes and save clinician time through faster decision-making at the point-of-care,' Prof. Harris continued. 'Diagnosing quickly and treating appropriately with the help of CDS means better care, better patient outcomes, and better use of invaluable healthcare resources.' Over 100 independent studies of UpToDate associate the use of the resource with clinician time savings and improvements on key hospital quality and efficiency metrics such as length of stay, medical errors, and unnecessary diagnostic testing. About Wolters Kluwer Wolters Kluwer (EURONEXT: WKL) is a global leader in information, software solutions and services for professionals in healthcare; tax and accounting; financial and corporate compliance; legal and regulatory; corporate performance and ESG. We help our customers make critical decisions every day by providing expert solutions that combine deep domain knowledge with technology and services. Wolters Kluwer reported 2024 annual revenues of €5.9 billion. The group serves customers in over 180 countries, maintains operations in over 40 countries, and employs approximately 21,600 people worldwide. The company is headquartered in Alphen aan den Rijn, the Netherlands. For more information, visit follow us on LinkedIn, Facebook, YouTube and Instagram.
Daily Mirror
08-07-2025
- Health
- Daily Mirror
'Groundbreaking' drug that can 'delay diabetes for years'
Teplizumab trains the immune system to stop attacking pancreatic cells, delaying the need for insulin by an average of three years A 'revolutionary' medication designed to slow the progression of type 1 diabetes is currently being tested by a small number of patients across the UK. Teplizumab, which has already received approval in the US, works by teaching the immune system to stop attacking pancreatic cells, postponing the requirement for insulin by an average of three years. In type 1 diabetes, the immune system targets insulin-producing cells within the pancreas, resulting in the body's inability to regulate blood sugar levels. When blood sugar becomes too elevated or drops too low, it can lead to severe health complications and potentially prove fatal. People with type 1 diabetes consequently require daily insulin injections. Dentist and mother-of-two Hannah Robinson, from Devon, has become the first adult in the UK to trial the medication in hopes of delaying the onset of her condition. She is receiving treatment at the Royal Devon University Healthcare NHS Foundation Trust following the discovery during her pregnancy that she was in the preliminary stages of developing type 1 diabetes. A small group of individuals are being administered the treatment on an individual assessment basis whilst it undergoes evaluation for broader NHS implementation, reports Devon Live. The 36-year-old explained: "For me, this new drug offers more freedom and the chance to focus on my health before I have to start thinking differently and managing life as somebody needing daily insulin. This isn't just about what I eat or monitoring my glucose, it is also about having more control and not feeling defined by my condition. "This treatment could potentially pave the way for a future cure for type 1 diabetes, which is incredible. I feel very lucky to be part of this." The breakthrough medication teplizumab requires administration during the condition's initial phases to achieve maximum effectiveness. Dr Nick Thomas, a diabetes specialist and academic clinical lecturer at the University of Exeter, explained: "This new treatment represents a really exciting shift in how we manage type 1 diabetes. For the first time ever, we will be able to provide targeted treatment early enough in the process to alter the underlying immune process, aiming to slow down how quickly people need insulin. "Approximately half of all type 1 diabetes cases develop in adulthood, and Hannah will be the first adult in the UK to receive this treatment. My hope is that in the future, we may be able to stop people with early type 1 diabetes from needing insulin at all." Specialists at the Royal Devon and the University of Exeter are utilising genetic analysis and additional screening methods to identify individuals at elevated risk of developing type 1 diabetes. The hope is that more patients could be offered the medication to postpone the onset of type 1. Dr Lucy Chambers, head of research impact and communications at Diabetes UK, said: "For people in the early stages of type 1 diabetes, teplizumab offers a groundbreaking opportunity to buy them precious extra years insulin-free. Right now, it's only available in research settings. "While the excitement is real, urgent work is still needed to ensure it reaches everyone who could benefit. That means securing a UK licence for teplizumab, establishing national screening programmes to identify people with early-stage type 1 diabetes before symptoms appear, and preparing the NHS to deliver this treatment at scale. "Diabetes UK is proud to be at the forefront of these efforts, funding pioneering research and working closely with the NHS towards a future where immunotherapies become the first-line treatment for tackling the autoimmune attack at the root of type 1 diabetes." Professor Richard Oram, a consultant physician at the Royal Devon and professor at the University of Exeter, added: "Excitingly, teplizumab is the first drug with the potential to delay type 1 diabetes, but needs to be given before clinical diagnosis due to high blood glucose. "It is really important to find new and improved approaches for identifying individuals at elevated risk."
Powys County Times
08-07-2025
- Health
- Powys County Times
‘Groundbreaking' drug could slow down progression of type 1 diabetes
A 'groundbreaking' drug to slow down the development of type 1 diabetes is being tried by a handful of patients in the UK. Teplizumab, which is already approved in the US, trains the immune system to stop attacking pancreatic cells, delaying the need for insulin by an average of three years. With type 1 diabetes, the immune system attacks insulin-producing cells in the pancreas, meaning blood sugar levels are no longer regulated by the body. If blood sugar is too high or low, it can cause serious health problems and even death. People with type 1 therefore need daily insulin. Dentist and mother-of-two, Hannah Robinson, from Devon, is the first adult in the UK to try the drug in the hope it can delay the condition. She is having treatment at the Royal Devon University Healthcare NHS Foundation Trust after discovering during pregnancy she was in the early stages of developing type 1. A handful of people are being given the medicine on a case-by-case basis while it is reviewed for wider use on the NHS. The 36-year-old said: 'For me, this new drug offers more freedom and the chance to focus on my health before I have to start thinking differently and managing life as somebody needing daily insulin. 'This isn't just about what I eat or monitoring my glucose, it is also about having more control and not feeling defined by my condition. 'This treatment could potentially pave the way for a future cure for type 1 diabetes, which is incredible. I feel very lucky to be part of this.' The new drug teplizumab must be given at the earliest stage of the disease to be effective. Dr Nick Thomas, diabetes consultant and academic clinical lecturer at the University of Exeter, said: 'This new treatment represents a really exciting shift in how we manage type 1 diabetes. 'For the first time ever, we will be able to provide targeted treatment early enough in the process to alter the underlying immune process, aiming to slow down how quickly people need insulin. 'Approximately half of all type 1 diabetes cases develop in adulthood, and Hannah will be the first adult in the UK to receive this treatment. 'My hope is that in the future, we may be able to stop people with early type 1 diabetes from needing insulin at all.' Experts at the Royal Devon and the University of Exeter are using genetics and other testing to spot people at high risk of developing type 1 diabetes. The hope is more people could be offered the drug to delay type 1. Dr Lucy Chambers, head of research impact and communications at Diabetes UK, said: 'For people in the early stages of type 1 diabetes, teplizumab offers a groundbreaking opportunity to buy them precious extra years insulin-free. 'Right now, it's only available in research settings – and while the excitement is real, urgent work is still needed to ensure it reaches everyone who could benefit. 'That means securing a UK licence for teplizumab, establishing national screening programmes to identify people with early-stage type 1 diabetes before symptoms appear, and preparing the NHS to deliver this treatment at scale. 'Diabetes UK is proud to be at the forefront of these efforts – funding pioneering research and working closely with the NHS towards a future where immunotherapies become the first-line treatment for tackling the autoimmune attack at the root of type 1 diabetes.' Professor Richard Oram, consultant physician at the Royal Devon and professor at the University of Exeter, said: 'Excitingly, teplizumab is the first drug with the potential to delay type 1 diabetes, but needs to be given before clinical diagnosis due to high blood glucose. 'It is really important to find new and improved approaches for identifying individuals at elevated risk.'
Glasgow Times
08-07-2025
- Health
- Glasgow Times
‘Groundbreaking' drug could slow down progression of type 1 diabetes
Teplizumab, which is already approved in the US, trains the immune system to stop attacking pancreatic cells, delaying the need for insulin by an average of three years. With type 1 diabetes, the immune system attacks insulin-producing cells in the pancreas, meaning blood sugar levels are no longer regulated by the body. If blood sugar is too high or low, it can cause serious health problems and even death. People with type 1 therefore need daily insulin. Dentist and mother-of-two, Hannah Robinson, from Devon, is the first adult in the UK to try the drug in the hope it can delay the condition. She is having treatment at the Royal Devon University Healthcare NHS Foundation Trust after discovering during pregnancy she was in the early stages of developing type 1. Hannah Robinson discovered during pregnancy she was in the early stages of developing type 1 diabetes (Family handout/Royal Devon University Healthcare NHS Foundation Trust/PA) A handful of people are being given the medicine on a case-by-case basis while it is reviewed for wider use on the NHS. The 36-year-old said: 'For me, this new drug offers more freedom and the chance to focus on my health before I have to start thinking differently and managing life as somebody needing daily insulin. 'This isn't just about what I eat or monitoring my glucose, it is also about having more control and not feeling defined by my condition. 'This treatment could potentially pave the way for a future cure for type 1 diabetes, which is incredible. I feel very lucky to be part of this.' The new drug teplizumab must be given at the earliest stage of the disease to be effective. Dr Nick Thomas, diabetes consultant and academic clinical lecturer at the University of Exeter, said: 'This new treatment represents a really exciting shift in how we manage type 1 diabetes. 'For the first time ever, we will be able to provide targeted treatment early enough in the process to alter the underlying immune process, aiming to slow down how quickly people need insulin. 'Approximately half of all type 1 diabetes cases develop in adulthood, and Hannah will be the first adult in the UK to receive this treatment. 'My hope is that in the future, we may be able to stop people with early type 1 diabetes from needing insulin at all.' Teplizumab, which is already approved in the US, trains the immune system to stop attacking pancreatic cells, delaying the need for insulin by up to three years (Royal Devon University Healthcare NHS Foundation Trust/PA) Experts at the Royal Devon and the University of Exeter are using genetics and other testing to spot people at high risk of developing type 1 diabetes. The hope is more people could be offered the drug to delay type 1. Dr Lucy Chambers, head of research impact and communications at Diabetes UK, said: 'For people in the early stages of type 1 diabetes, teplizumab offers a groundbreaking opportunity to buy them precious extra years insulin-free. 'Right now, it's only available in research settings – and while the excitement is real, urgent work is still needed to ensure it reaches everyone who could benefit. 'That means securing a UK licence for teplizumab, establishing national screening programmes to identify people with early-stage type 1 diabetes before symptoms appear, and preparing the NHS to deliver this treatment at scale. 'Diabetes UK is proud to be at the forefront of these efforts – funding pioneering research and working closely with the NHS towards a future where immunotherapies become the first-line treatment for tackling the autoimmune attack at the root of type 1 diabetes.' Professor Richard Oram, consultant physician at the Royal Devon and professor at the University of Exeter, said: 'Excitingly, teplizumab is the first drug with the potential to delay type 1 diabetes, but needs to be given before clinical diagnosis due to high blood glucose. 'It is really important to find new and improved approaches for identifying individuals at elevated risk.'
South Wales Argus
08-07-2025
- Health
- South Wales Argus
‘Groundbreaking' drug could slow down progression of type 1 diabetes
Teplizumab, which is already approved in the US, trains the immune system to stop attacking pancreatic cells, delaying the need for insulin by an average of three years. With type 1 diabetes, the immune system attacks insulin-producing cells in the pancreas, meaning blood sugar levels are no longer regulated by the body. If blood sugar is too high or low, it can cause serious health problems and even death. People with type 1 therefore need daily insulin. Dentist and mother-of-two, Hannah Robinson, from Devon, is the first adult in the UK to try the drug in the hope it can delay the condition. She is having treatment at the Royal Devon University Healthcare NHS Foundation Trust after discovering during pregnancy she was in the early stages of developing type 1. Hannah Robinson discovered during pregnancy she was in the early stages of developing type 1 diabetes (Family handout/Royal Devon University Healthcare NHS Foundation Trust/PA) A handful of people are being given the medicine on a case-by-case basis while it is reviewed for wider use on the NHS. The 36-year-old said: 'For me, this new drug offers more freedom and the chance to focus on my health before I have to start thinking differently and managing life as somebody needing daily insulin. 'This isn't just about what I eat or monitoring my glucose, it is also about having more control and not feeling defined by my condition. 'This treatment could potentially pave the way for a future cure for type 1 diabetes, which is incredible. I feel very lucky to be part of this.' The new drug teplizumab must be given at the earliest stage of the disease to be effective. Dr Nick Thomas, diabetes consultant and academic clinical lecturer at the University of Exeter, said: 'This new treatment represents a really exciting shift in how we manage type 1 diabetes. 'For the first time ever, we will be able to provide targeted treatment early enough in the process to alter the underlying immune process, aiming to slow down how quickly people need insulin. 'Approximately half of all type 1 diabetes cases develop in adulthood, and Hannah will be the first adult in the UK to receive this treatment. 'My hope is that in the future, we may be able to stop people with early type 1 diabetes from needing insulin at all.' Teplizumab, which is already approved in the US, trains the immune system to stop attacking pancreatic cells, delaying the need for insulin by up to three years (Royal Devon University Healthcare NHS Foundation Trust/PA) Experts at the Royal Devon and the University of Exeter are using genetics and other testing to spot people at high risk of developing type 1 diabetes. The hope is more people could be offered the drug to delay type 1. Dr Lucy Chambers, head of research impact and communications at Diabetes UK, said: 'For people in the early stages of type 1 diabetes, teplizumab offers a groundbreaking opportunity to buy them precious extra years insulin-free. 'Right now, it's only available in research settings – and while the excitement is real, urgent work is still needed to ensure it reaches everyone who could benefit. 'That means securing a UK licence for teplizumab, establishing national screening programmes to identify people with early-stage type 1 diabetes before symptoms appear, and preparing the NHS to deliver this treatment at scale. 'Diabetes UK is proud to be at the forefront of these efforts – funding pioneering research and working closely with the NHS towards a future where immunotherapies become the first-line treatment for tackling the autoimmune attack at the root of type 1 diabetes.' Professor Richard Oram, consultant physician at the Royal Devon and professor at the University of Exeter, said: 'Excitingly, teplizumab is the first drug with the potential to delay type 1 diabetes, but needs to be given before clinical diagnosis due to high blood glucose. 'It is really important to find new and improved approaches for identifying individuals at elevated risk.'
